WO2020166708A1 - Nouvelle bactérie lactique et composition la contenant - Google Patents

Nouvelle bactérie lactique et composition la contenant Download PDF

Info

Publication number
WO2020166708A1
WO2020166708A1 PCT/JP2020/005854 JP2020005854W WO2020166708A1 WO 2020166708 A1 WO2020166708 A1 WO 2020166708A1 JP 2020005854 W JP2020005854 W JP 2020005854W WO 2020166708 A1 WO2020166708 A1 WO 2020166708A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
bacteria
flora
composition
group
Prior art date
Application number
PCT/JP2020/005854
Other languages
English (en)
Japanese (ja)
Inventor
祐子 板谷
井上　亮
Original Assignee
コンビ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンビ株式会社 filed Critical コンビ株式会社
Priority to JP2020572343A priority Critical patent/JP7262127B2/ja
Publication of WO2020166708A1 publication Critical patent/WO2020166708A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the food or drink of the present invention is for the control of the bacterial composition balance contained in the indigenous flora, for the reduction of Lactomospiraceae bacteria, Acinetobacter bacteria, Bacteroides bacteria or Prevotella bacteria in the indigenous flora, mucoadhesive bacterial flora or For increasing the amount of Musispirillum bacteria in the intestinal flora, for suppressing weight loss, for suppressing DAI score, for suppressing diarrhea or fecal bleeding, for reducing strains involved in inflammation, for suppressing diseases or symptoms related to inflammation It can be sold as food or drink with the intended use indicated.
  • the content of the 2031 strain is appropriately set depending on the aspect of the cosmetic product and the administration subject, but is in the range of 1 ⁇ 10 6 to 1 ⁇ 10 12 cfu/g or 1 ⁇ 10 6 to 1 ⁇ 10 12 cfu/ml. It is preferable that it is in the range of 1 ⁇ 10 7 to 1 ⁇ 10 11 cfu/g or 1 ⁇ 10 7 to 1 ⁇ 10 11 cfu/ml.
  • the administration method in the present invention is preferably oral. However, it is not particularly limited as long as it does not impair the effects of the present invention, and the lactic acid bacterium strain of the present invention may be administered to a subject by other methods such as tube, enteral, transdermal (application, etc.). ..
  • Example 1 Confirmation test of effect of administration of lactic acid bacteria on mucoadhesive flora and intestinal flora
  • Two-week-old C57BL/6N mice purchased from Japan SLC were acclimatized for 7 days, and then weaned at three weeks. Then, the mice were made to have an equal weight so that the control group (C group) and Lactobacillus crispatus CFF No.
  • the breeding room was lit at 8 o'clock and turned off at 8 o'clock in a 12-hour light-dark cycle, and the room temperature was set to 25 ⁇ 2°C.
  • Fig. 3A The results of the bacterial flora structure analysis by metagenomic analysis of the mucoadhesive bacterial flora of the colon were as shown in Fig. 3A.
  • Lactobacillus crispatus CFF No The occupancy rate of Acinetobacter bacteria in the 2031 strain-administered group (L group) was significantly lower than that in the control group (C group) (FIG. 3B, Wilcoxon/Kruskal-Wallis test (rank sum)). , P ⁇ 0.05).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une souche de Lactobacillus crispatus, la séquence nucléotidique du gène de l'ARNr 16S de ladite souche présentant au moins 95 % d'identité avec la séquence nucléotidique indiquée dans SEQ ID NO : 1.
PCT/JP2020/005854 2019-02-15 2020-02-14 Nouvelle bactérie lactique et composition la contenant WO2020166708A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020572343A JP7262127B2 (ja) 2019-02-15 2020-02-14 新規乳酸菌およびそれを含有する組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-025895 2019-02-15
JP2019025895 2019-02-15

Publications (1)

Publication Number Publication Date
WO2020166708A1 true WO2020166708A1 (fr) 2020-08-20

Family

ID=72044106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/005854 WO2020166708A1 (fr) 2019-02-15 2020-02-14 Nouvelle bactérie lactique et composition la contenant

Country Status (3)

Country Link
JP (1) JP7262127B2 (fr)
TW (1) TWI824110B (fr)
WO (1) WO2020166708A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112458007A (zh) * 2020-11-10 2021-03-09 深圳华大生命科学研究院 用于预防和/或治疗生殖道菌群紊乱相关疾病的卷曲乳杆菌

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004051530A (ja) * 2002-07-19 2004-02-19 Combi Corp 腸内菌叢改善剤及びそれを含有する飲食品
JP2011503225A (ja) * 2007-11-20 2011-01-27 エヌ．ブイ．・ヌートリシア シンバイオティクス組成物
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
JP2018500918A (ja) * 2015-01-09 2018-01-18 ジェン−プローブ・インコーポレーテッド 細菌性膣症を診断するための方法および組成物
JP2018508225A (ja) * 2015-03-16 2018-03-29 ジェン−プローブ・インコーポレーテッド 細菌核酸を検出し細菌性膣炎を診断するための方法および組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7327773B2 (ja) * 2016-03-04 2023-08-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 微生物共同体およびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004051530A (ja) * 2002-07-19 2004-02-19 Combi Corp 腸内菌叢改善剤及びそれを含有する飲食品
JP2011503225A (ja) * 2007-11-20 2011-01-27 エヌ．ブイ．・ヌートリシア シンバイオティクス組成物
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
JP2018500918A (ja) * 2015-01-09 2018-01-18 ジェン−プローブ・インコーポレーテッド 細菌性膣症を診断するための方法および組成物
JP2018508225A (ja) * 2015-03-16 2018-03-29 ジェン−プローブ・インコーポレーテッド 細菌核酸を検出し細菌性膣炎を診断するための方法および組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARREOLA, A. R. ET AL.: "PROBIOTIC BACTERIA IN HUMAN MILK AFTER SPRY-DRIED", ANNALS OF NUTRITION AND METABOLISM, vol. 72, 2018, pages 67 *
OJALA, T. ET AL.: "Genome Sequence of Lactobacillus crispatus ST1", JOURNAL OF BACTERIOLOGY, vol. 192, no. 13, 2010, pages 3547 - 3548, XP055732199 *
PAVLOVA, S. I. ET AL.: "Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences", JOURNAL OF APPLIED MICROBIOLOGY, vol. 92, 2002, pages 451 - 459, XP002255554, DOI: 10.1046/j.1365-2672.2002.01547.x *
TOBITA, KEISUKE ET AL: "About functionality and safety of Lactobacillus crispatus KT-11 as food", NEW FOOD INDUSTRY, vol. 57, no. 10, pages 2015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112458007A (zh) * 2020-11-10 2021-03-09 深圳华大生命科学研究院 用于预防和/或治疗生殖道菌群紊乱相关疾病的卷曲乳杆菌

Also Published As

Publication number Publication date
TWI824110B (zh) 2023-12-01
TW202045715A (zh) 2020-12-16
JP7262127B2 (ja) 2023-04-21
JPWO2020166708A1 (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
JP5261617B2 (ja) 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料
JP5300772B2 (ja) 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料
JPWO2018180728A1 (ja) 炎症制御遺伝子の発現促進用組成物
CN110325198A (zh) 益生菌在治疗和/或预防银屑病中的用途
TWI565471B (zh) Oral use of DNA damage repair promoters and elastase activity inhibitors
JP2021506299A (ja) 認知的及び精神的健康のためのプロバイオティクス
WO2019045037A1 (fr) Composition permettant de favoriser la production d'acide hyaluronique
JP2021508462A (ja) セルピン産生
KR102368628B1 (ko) Iv형 알레르기용 조성물
WO2020166708A1 (fr) Nouvelle bactérie lactique et composition la contenant
KR20180134601A (ko) 임산부를 위한 기능성 유산균 조성물
US20240011067A1 (en) Limosilactobacillus reuteri strain with high riboflavin production and uses thereof
JP2012180288A (ja) 抗菌剤
JP6648348B1 (ja) Ｉ型アレルギー用組成物
JP7419404B2 (ja) 抗老化用組成物
TWI734333B (zh) 減少體脂肪之益生菌株及其組合物與用途
CN112804887A (zh) 线粒体功能改善剂
JP2021045054A (ja) 抗憂うつ用組成物、幸福感向上用組成物
JP7498455B2 (ja) ミトコンドリア機能改善剤
JP7326075B2 (ja) 腎機能障害の予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物
WO2024055983A1 (fr) Composition de protéine de graine de citrouille et son utilisation
WO2022085456A1 (fr) Composition pour maladie intestinale inflammatoire
WO2024101341A1 (fr) Composition pour nouveau-nés ou nourrissons
JP2022184424A (ja) 内臓脂肪低減剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20754999

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020572343

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20754999

Country of ref document: EP

Kind code of ref document: A1